EDIT (Editas Medicine) Institutional Ownership: 61.33% (As of Jul. 11, 2026)


EDIT Editas Medicine Inc EDIT
51 GF Score
Price $3.26
GF Value $1.83
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine Institutional Ownership?

Editas Medicine EDIT -0.76% 51 Institutional Ownership is 61.33% as of Jul. 11, 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.83 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Editas Medicine's institutional ownership is 61.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Editas Medicine's Insider Ownership is 1.91%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Editas Medicine's Float Percentage Of Total Shares Outstanding is 99.83%.

Editas Medicine Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Editas Medicine's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine Institutional Ownership Chart

Editas Medicine Historical Data

The historical data trend for Editas Medicine can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 29.11 28.01 28.52 29.75 29.60 29.31 30.56 30.19 20.99 21.66
EDIT
51GF Score
Editas Medicine Inc EDIT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Editas Medicine Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 61.33% mean?
Editas Medicine (EDIT) has a Institutional Ownership of 61.33% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Editas Medicine and its competitors.
Is Editas Medicine's Institutional Ownership too high?
Editas Medicine's current Institutional Ownership is 61.33%. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Institutional Ownership compare to SGMT and AUTL?
Editas Medicine's Institutional Ownership of 61.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Editas Medicine and its competitors. Editas Medicine's current Institutional Ownership is 61.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $3.26 — trading 78.1% above its estimated fair value. The current Institutional Ownership is 61.33%. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Institutional Ownership is 61.33% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $3.26 is trading 78.1% above its estimated GF Value™ of $1.83. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • Institutional Ownership: 61.33%
  • GF Value™: $1.83 vs. price of $3.26 (78.1% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score

Get the complete analysis for EDIT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.26
Price
$1.83
GF Value